Riskpilot← Back to searchSign inGet full accessPHARMA PRODUCTION AS
ASActiveOrg 920049060Karihaugveien 22, 1086 OsloManufacture of pharmaceutical preparations · NACE 2120Est. 201717 employees
Revenue 2024
NOK 29,4M
+38% vs 2023
EBITDA margin
-12.3%
+52% vs 2023
Equity ratio
2.3%
Financial strength
Net profit 2024
NOK -3,6M
-203% vs 2023
| Revenue | NOK 29,4M | +38% |
| EBITDA | NOK -3,6M | +52% |
| Net profit | NOK -3,6M | -203% |
| Total assets | NOK 20,1M | +30% |
| Equity | NOK 465K | -89% |
| Employees | 17 | — |
Legal name
PHARMA PRODUCTION AS
Org number
920049060
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
11. desember 2017
Share capital
NOK 300 000
Employees
17 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Produksjon, pakking og ompakking av farmasøytiske produkter, herunder legemidler, samt aktiviteter og investeringer som vil være formålstjenlig med slik virksomhet.
Address
Karihaugveien 22, 1086 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 11 125 | 13 244 | 19 717 | 17 459 | 19 798 | 21 362 | 29 405 |
| Staff expenses | −0 | −2 721 | −7 559 | −9 326 | −8 505 | −9 804 | −10 573 | −12 285 |
| EBITDA | 0 | −666 | −7 924 | −4 312 | −4 490 | −6 162 | −7 595 | −3 619 |
| Depreciation & amort. | −0 | −44 | −262 | −266 | −304 | −278 | −332 | −217 |
| EBIT | 0 | −710 | −8 186 | −4 578 | −4 794 | −6 439 | −7 927 | −3 835 |
| Net financials | 0 | −74 | −84 | −459 | −557 | −639 | −1 074 | −766 |
| Profit before tax | 0 | −783 | −8 270 | −5 037 | −5 350 | −7 079 | −9 001 | −4 601 |
| Tax | 0 | 1 | −1 993 | 1 993 | −0 | −0 | −7 816 | −1 012 |
| Net profit | −0 | −785 | −6 277 | −7 030 | −5 350 | −7 079 | −1 185 | −3 589 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 3 324 | 7 362 | 7 766 | 18 934 | 11 343 | 23 618 | 15 450 | 20 051 |
| Equity | 58 | −726 | −7 004 | 317 | 317 | 5 239 | 4 054 | 465 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 266 | 8 088 | 14 770 | 18 617 | 11 025 | 18 379 | 11 396 | 19 586 |
| Total debt | 3 266 | 8 088 | 14 770 | 18 617 | 11 025 | 18 379 | 11 396 | 19 586 |
EBITDA margin
-12.3%
This company
15.8%
Market median
-178% vs market
20172024
Equity ratio
2.3%
This company
38.2%
Market median
-94% vs market
20172024
Return on equity
-771.8%
This company
18.4%
Market median
-4295% vs market
20172024
Net profit margin
-12.2%
This company
8.1%
Market median
-251% vs market
20172024
Asset turnover
1.47×
This company
1.12×
Market median
+31% vs market
20172024
Debt / equity
42.12×
This company
0.62×
Market median
-6694% vs market
20172024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dne Pharma As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Calin Invest As
PHARMA PRODUCTION AS Board members of PHARMA PRODUCTION AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Esther Elisabeth Paust | Board of Directors | 0 companies |
| Geir Ove Engeset | Chairman | 0 companies |
| Geir Ivar Simonsen | Chairman | 0 companies |